IP Library Granted Patent US 10,837,962
Granted Patent B2
US 10,837,962 · App. 15/848,301 · Granted Nov 17, 2020

Method and associated device for rapid detection of target biomolecules with enhanced sensitivity

Inventors: Matthew Jeremiah Misner (Delanson, NY); Gregory Andrew Grossmann (Halfmoon, NY); Cathryn Ellen Olsen (Wilton, NY); John Richard Nelson (Clifton Park, NY); Brian Christopher Bales (Niskayuna, NY); David Roger Moore (Rexford, NY); Paul Michael Smigelski, Jr. (Glenville, NY)
Assignee: GENERAL ELECTRIC COMPANY
G01N33/5695B01D15/363B01L3/5023G01N1/4005G01N33/54366B01L2200/0631B01L2200/10B01L2300/0825G01N2001/4011G01N2333/35G01N2405/06G01N2469/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,837,962
App. No.
15/848,301
Granted
Nov 17, 2020
Kind
B2
Abstract

A rapid detection method of a target biomolecule comprising an antigenic moiety is provided. The method includes providing a source biological sample comprising the target biomolecule; contacting the source biological sample to an ion-exchange medium; eluting the captured-target biomolecule from the ion-exchange medium as an eluate, and loading the eluate to a rapid diagnostic testing device comprising an antibody. The eluate comprises a concentrated form of the biomolecule in a solution having a salt concentration greater than 150 mM. A concentration of the target biomolecule in the eluate is in a range from about 2× to 25× compared to a concentration of the biomolecule in the source biological sample. The target biomolecule binds to the antibody under the salt concentration of greater than 150 mM. A device for rapid detection of target biomolecule is also provided.

Claims (19)

1. A rapid detection method of a target biomolecule, comprising:

contacting a source biological sample comprising the target biomolecule to an ion-exchange medium comprising one or more ligands to capture the target biomolecule and form a captured-target biomolecule, the target biomolecule comprising an antigenic moiety;

eluting, using an elution buffer having a buffer salt concentration greater than 150 mM, the captured-target biomolecule from the ion-exchange medium as an eluate comprising a concentrated form of the target biomolecule in a solution, wherein a concentration of the target biomolecule in the eluate is in a range from about 2× to 25× compared to a concentration of the target biomolecule in the source biological sample, and wherein the solution has a salt concentration greater than 150 mM; and

loading the eluate comprising the concentrated form of the target biomolecule in the solution to a rapid diagnostic testing device comprising an antibody, wherein the target biomolecule binds to the antibody under the salt concentration of greater than 150 mM.

2. The method of claim 1 , wherein the target biomolecule is a glycolipid.

3. The method of claim 1 , wherein the target biomolecule is a tuberculosis-lipoarabinomannan (TB-LAM).

4. The method of claim 1 , wherein the target biomolecule binds to the antibody under the salt concentration in a range from about 0.5M to about 2M.

5. The method of claim 1 , wherein the target biomolecule binds to the antibody under the salt concentration of about 1.3M.

6. The method of claim 1 , wherein the elution of the captured-target biomolecule from the ion-exchange medium is effected under a salt concentration in a range from about 0.5M to about 2M.

7. The method of claim 1 , wherein the eluate comprising the concentrated form of the target biomolecule is loaded without any dilution to the rapid diagnostic testing device comprising an antibody.

8. The method of claim 1 , further comprising diluting the source biological sample comprising the target biomolecule by at least 2× to form a diluted biological sample.

9. The method of claim 1 , further comprising diluting the source biological sample comprising the target biomolecule by 4× to form a diluted biological sample.

10. The method of claim 1 , wherein the rapid diagnostic testing device comprises a lateral flow assay (LFA) device, an enzyme linked immuno-sorbent assay (ELISA) device, or a combination thereof.

11. The method of claim 10 , wherein the rapid diagnostic testing device comprises a lateral flow assay (LFA) device.

12. The method of claim 1 , wherein the source biological sample comprises urine, blood, feces, sweat, saliva, mucous, milk, semen, serum, plasma, sputum, tears, tissue, or combinations thereof.

13. The method of claim 12 , wherein the source biological sample is urine.

14. The method of claim 1 , wherein the ion-exchange medium comprises an ion exchange material, an ion-exchange membrane, or an ion-exchange matrix.

15. The method of claim 1 , wherein the one or more ligands comprise anionic ligands.

16. The method of claim 15 , wherein the anionic ligands are quaternary ammonium ion, or dimethyl aminoethyl (DMAE) groups.

Assignments (5)
QUITCLAIM ASSIGNMENT Recorded Sep 18, 2025
From: EDISON INNOVATIONS LLC
To: BLUE RIDGE INNOVATIONS, LLC
Reel/Frame 072938/0793 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2025
From: GENERAL ELECTRIC COMPANY
To: GE INTELLECTUAL PROPERTY LICENSING, LLC
Reel/Frame 070636/0815 →
CHANGE OF NAME Recorded Mar 26, 2025
From: GE INTELLECTUAL PROPERTY LICENSING, LLC
To: DOLBY INTELLECTUAL PROPERTY LICENSING, LLC
Reel/Frame 070643/0907 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2025
From: DOLBY INTELLECTUAL PROPERTY LICENSING, LLC
To: EDISON INNOVATIONS, LLC
Reel/Frame 070293/0273 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2017
From: MISNER, MATTHEW JEREMIAH; GROSSMANN, GREGORY ANDREW; OLSEN, CATHRYN ELLEN; NELSON, JOHN RICHARD; BALES, BRIAN CHRISTOPHER; MOORE, DAVID ROGER; SMIGELSKI, PAUL MICHAEL
To: GENERAL ELECTRIC COMPANY
Reel/Frame 044446/0845 →